stockrowSpyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
- EPS
- −624.8%
- Free cash flow
- −108.8%
Quarter to September 2026, against a year earlier
Follow SYRE
Alert me
Spyre Therapeutics, Inc. (SYRE) EPS (diluted)
Spyre Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$1.98, compared with −$4.42 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$3.07. Over the past ten years it has ranged from −$470.79 (fiscal 2015) to −$1.98 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 6 consecutive fiscal years. Spyre Therapeutics, Inc. ranks 378th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.98 | — |
| FY2024 | −$4.42 | — |
| FY2023 | −$13.76 | — |
| FY2022 | −$24.75 | — |
| FY2021 | −$25.00 | — |
| FY2020 | −$38.00 | — |
| FY2019 | −$61.25 | — |
| FY2018 | −$53.25 | — |
| FY2017 | −$45.00 | — |
| FY2016 | −$55.50 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$1.09 | — |
| Jun 2026 | −$0.36 | — |
| Mar 2026 | −$0.74 | — |
| Dec 2025 | −$0.89 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $7.37 |
| TGTX TG Therapeutics, Inc. compare | $2.74 |
| PTGX Protagonist Therapeutics, Inc. compare | $1.03 |
| CAI Caris Life Sciences,�Inc. compare | $0.33 |
| IBRX ImmunityBio, Inc. compare | −$0.97 |
| TWST Twist Bioscience Corporation compare | −$2.22 |
| SYRE Spyre Therapeutics, Inc. | −$3.07 |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$5.98 |
| CYTK Cytokinetics, Incorporated compare | −$6.04 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on SYRE
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement